As described, although palbociclib plus fulvestrant showed wonderful clinical efficacy as second-line therapy of women with HR+/HER2- advanced breast cancer, these estimates suggested that palbociclib plus fulvestrant arm, compared with placebo plus fulvestrant arm, is unlikely to be cost-effective from the perspective of the Chinese healthcare system at the WTP threshold of $34,138.28 per QALY in China. This evidence concerns the gene ERBB2 and breast carcinoma.